公司今日宣布,与ConjugateBio Inc.达成合作,天演将向合作方提供自主研发抗体,共同开发双特异性抗体偶联药物(ADC)。“ConjugateBio 优化抗体偶联药物(ADC)开发流程的能力令人印象深刻,我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合,ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势,我们很高兴能参与贡献...
Source Link公司今日宣布,与ConjugateBio Inc.达成合作,天演将向合作方提供自主研发抗体,共同开发双特异性抗体偶联药物(ADC)。“ConjugateBio 优化抗体偶联药物(ADC)开发流程的能力令人印象深刻,我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合,ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势,我们很高兴能参与贡献...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.